A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia; Lymphoma
- Focus Therapeutic Use
- 15 Sep 2017 Planned End Date changed from 1 Sep 2020 to 1 Apr 2021.
- 15 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2018.
- 10 Jun 2017 Biomarkers information updated